Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Eur Urol. 2017 Apr 8;73(2):168–175. doi: 10.1016/j.eururo.2017.03.036

Table 3.

Patients with high risk (PSA > 20 or prostatectomy Gleason score > 8 or prostatectomy stage pT3b/N1 [n = 323, 98 PCSM10]

Model OR (95% CI) p value AUC of model (95% CI) Increase in AUC from adding GC
GC (per 0.1 unit) 1.37 (1.21, 1.54) <0.001 0.69 (0.62, 0.76) (NA)
GC (per 0.1 unit), adjusted for base model 1.31 (1.15, 1.48) <0.001 0.73 (0.67, 0.78) (0.04)
GC (per 0.1 unit), adjusted for CAPRA-S 1.33 (1.17, 1.50) <0.001 0.69 (0.62, 0.75) (0.08)
GC (>0.6 vs. ≤0.6) 4.51 (2.72, 7.48) <0.001 0.67 (0.62, 0.73) (NA)
GC (>0.6 vs. ≤0.6) + base model 3.90 (2.27,6.70) <0.001 0.74 (0.69, 0.80) (0.06)
GC (>0.6 vs. ≤0.6) + CAPRA-S 3.96 (2.35, 6.69) <0.001 0.69 (0.63, 0.76) (0.08)

AUC = area under the curve; CAPRA-S = Cancer of the Prostate Risk Assessment Postsurgical; CI = confidence interval; GC = Decipher genomic classifier; NA = not applicable; OR = odds ratio; PCSM = prostate cancer-specific mortality; PSA = prostate-specific antigen.